EW Q2 2024 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.4B+7.0% YoY

Gross Profit

$1.1B78.5% margin

Operating Income

$365M26.3% margin

Net Income

$364M26.2% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

$372M

Free Cash Flow

$286M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$10.1B

Total Liabilities

$2.6B

Stockholders' Equity

$7.4B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$1.3B	+7.0%
Gross Profit	$1.1B	$1.0B	+6.2%
Operating Income	$365M	$371M	-1.6%
Net Income	$364M	$307M	+18.4%

Revenue Segments

Transcatheter Heart Valves

$1.0B75%

Surgical Heart Valve Therapy

$264M19%

Transcatheter Mitral And Tricuspid Therapies

$83M6%

Geographic Segments

UNITED STATES

$817M59%

Europe

$336M24%

Rest of World

$146M11%

JAPAN

$87M6%